The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

MethodologyData used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report• Provides a snapshot of the therapeutics pipeline activity for “C5a Receptor Antagonist• Features the C5a Receptor Antagonist pipeline across the complete product development cycle including all clinical and non-clinical stages• Offers detailed therapeutic product profiles of C5a Receptor Antagonist with key coverage of developmental activities including licensing & collaboration deals, patent details. designations, technologies, indications and chemical information• Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration• Coverage of dormant and discontinued pipeline projects across “C5a Receptor Antagonist

Reasons to Buy• Establish a comprehensive understanding of the current pipeline scenario across C5a Receptor Antagonist to formulate effective R&D strategies• Assess challenges and opportunities that influence C5a Receptor Antagonist research & development (R&D)• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage• Identify and understand the sought after therapy areas and indications for “C5a Receptor Antagonist• Identify the product attributes and use it for target finding, drug repurposing, and precision medicine• Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for C5a Receptor Antagonist to enhance and expand business potential and scope• Plan prospective mergers and acquisitions effectively by identifying key players in this area and their most promising pipeline therapeutics and developmental progress• Our extensive domain knowledge on therapy areas supports the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs

With the first prophylactic cancer vaccine Gardasil approved in 2006 and therapeutic cancer vaccine Sipuleucel-T (Provenge) approved in 2010, cancer vaccines is a proven hot treatment modality which is now turbocharged with the event of immune-checkpoint inhibitors. Cancer Vaccines: Analytical Tool is the most up to date and comprehensive...

The first Antibody-Drug Conjugate (ADC) to receive marketing approval from the US Food and Drug Administration (FDA) was gemtuzumab ozogamicin (Mylotarg) in 2000 which represents a powerful, emerging novel class of anticancer treatment agents that combines the selectivity of targeted treatment with the cytotoxic potency of chemotherapy drugs. Conjugated...

About Hydronephrosis Hydronephrosis is a condition when the inside of the kidney gets dilated or stretched and usually analgesics and drugs for kidney stones are used as therapeutics for hydronephrosis. Technavio’s analysts forecast the Global Hydronephrosis Therapies Market to grow at a CAGR of 9.14% during the...